- Research Plus
- Portfolios & Watchlists
- Charting
- Screening Tools
- Visual Tools
- Education Guides
- UK Shares
- Funds
- International Shares
- Gilts
- Currencies
- Commodities
- Company Diary
- Free Brochures
- ETF Centre
- Real Time
Incyte Corp. (INCY)
Index:
- Change Today: $-1.19
- 52 Week High: $110.57
- 52 Week Low: $60.81
- Currency: US Dollars
- Shares Issued: 198.46m
- Volume: 136
- Market Cap: $19,673m
- RiskGrade: 196
- Beta: 0.05
Latest ShareCast News
FDA grants EUA for Eli Lilly treatment in conjunction with Remdesivir
By Alexander Bueso
Date: Friday 20 Nov 2020
(Sharecast News) - The Food and Drug Administration has granted Emergency Use Approval for baricitinib, a treatment for Covid-19 developed jointly by Eli Lilly and Incyte, in combination with Gilead Sciences's remdesivir.
No recent information was found.
Incyte Corp. Market Data
| Currency | US Dollars |
| Share Price | $ 99.13 |
| Change Today | $ -1.19 |
| % Change | -1.19 % |
| 52 Week High | $110.57 |
| 52 Week Low | $60.81 |
| Volume | 136 |
| Shares Issued | 198.46m |
| Market Cap | $19,673m |
| Beta | 0.05 |
| RiskGrade | 196 |
What The Brokers Say
| Strong Buy | 7 |
| Buy | 5 |
| Neutral | 10 |
| Sell | 2 |
| Strong Sell | 0 |
| Total | 24 |
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.
You are here: research
Digital Look Ltd,
10 Lower Thames St,
London EC3R 6EN
10 Lower Thames St,
London EC3R 6EN